Featured
Is the era of rising drug prices over?
The prices of new drugs at launch rose by over a third from 2022 to 2025, but the trend came to an abrupt end in the last year. Is this the start of a new era?
Regulatory & Reimbursement
Big names on NZ's November PTAC meeting
The advisory committee will consider drugs for recommendation to Pharmac for funding medicines
Latest
Health leaders of tomorrow start here
AbbVie has thrown its support behind the Future Health Leaders Program alongside Research Australia and the CSIRO to inspire the next generation of changemakers
Pipeline & Intellectual Property
Six-way legal stoush over $47.5M market
J&J has started proceedings to prevent four companies from launching generic versions of one of its drugs, but a fifth decided it also wanted to get involved
Pipeline & Intellectual Property
Astellas bets $1.89B on Aussie drug
Astellas Pharma has agreed to pay up to $1.89 billion for rights to develop and commercialise a pre-clinical immuno-oncology candidate
Government & Policy
Biologics finally move to first line in paediatric Crohn's
Acting PBAC Chair tells Senate Estimates that "sponsors are just not commercially enticed" to paediatric populations
Industry & Companies
MA lands its 50th member
A new member of Medicines Australia has seen the ranks of the industry organisation swell to 50
Featured
Patients pick favourite pharma
One company shot up the rankings by four places to be declared the top Big Pharma when it comes to corporate reputation, judged by diabetes patients
Pipeline & Intellectual Property
CEO stands by takeover despite US$1.9B hit
Insists the phase 3 fail of one of the deal's key assets is just a “bump” for the company and the price of pioneering science
Regulatory & Reimbursement
Action urged on 'dangerously under-recognised' disease
Boehringer has launched a report to increase public awareness and exhort government action on a disease that makes people feel their lungs are concrete
Industry & Companies
Aussie repurposer swaps shares for NZ start-up
The move gives access to a repurposed treatment for patients with multiple sclerosis, with the buy raising capital to fund the drug's trial
Industry & Companies
Top pharma employers as voted by staff
Twelve pharmas made the Top 20 science-focused companies to work for list, voted in by the people who work there. See who made the cut
Leadership & People
Ex-Aussie GM lands top new role
Less than three years after leaving Australia, this leader who spent five years heading the ANZ team has won another promotion
Government & Policy
Dept boasts faster medicines access
Annual Report hails 100 per cent strike rate on six-months-to-listing target but the fine print reveals the numbers don't tell the full story
Pipeline & Intellectual Property
Cancer drug's 'unprecedented' trial results
Slashes the risk of death by 58% in this lung cancer patient cohort, with the company describing the findings as a watershed moment in the management of the disease
Jobs & Workplace
Ex-BMS exec wins Aussie Country Lead role
After more than 15 years at BMS, this well-known executive has joined a Canadian company to lead its Australian operations
Industry & Companies
CSL grilled by many cooks
Shareholders turned up the heat at the company's AGM this morning, with the outgoing Chair conceding it had overpaid for an US$11.7B acquisition
Jobs
Popular
Is pharma finally in a good mood?
The bright future pharma has been dreaming of has arrived... at least for some with positive sentiment on a steep climb - except when it comes to the prospect of finding a new job
Featured
Pharma exec shares life lessons after horror bus crash
National Sales Manager Sharyn Junkeer shares the lessons she's painfully learned about life and career after suffering critical injuries in a horror bus crash
Regulatory & Reimbursement
Four pharmas start run for Govt funding
A company navigating Australia's reimbursement system for the first time is kicking off the race for Government funding
Government & Policy
Butler talks security in the wake of Haines attack
Health Minister has not upped his security in the last week, but concedes changes likely need to be made
Leadership & People
Company announces another leadership change
Long-time boss to be replaced next year by someone whose history with the organisation runs just as deep
Pipeline & Intellectual Property
Secret data leak, landmark results... then a share tumble
Over a tumultuous few hours, impressive data on the world's first mRNA cancer vaccine was leaked, then praised, before a tumble on the stock market
Industry & Companies
Astellas turns up the heat on politicians
Temperatures were high when three Sydney MPs visited the pharma's Macquarie Park office. Find out why
Regulatory & Reimbursement
PBAC-ticked gene therapy wins TGA nod
A new form of a gene therapy expands the indicated population to catch those who weren't diagnosed in time
Jobs & Workplace
Farewells dominate Aussie pharma job moves
Departures from companies, Australia and even industry have dominated the latest round of job moves across pharma
- Leadership & People Ex-Aussie GM nabs top job with newcomer
- Leadership & People Pharma boss smashes two glass ceilings
- Awards LinkedIn names Australia's best workplaces
- Pipeline & Intellectual Property Aussies tapped for US gene project
- Government & Policy Australia's long road to closing CAR T gap
- Leadership & People CSL names ex-Aussie GM as new CEO
- Industry & Companies Arrotex signs deal for locally-developed med
- Jobs & Workplace Feeling disengaged? Here's what might be missing
- Regulation & Legal CSL slapped with investor class action
- Other News BioNTech opens Aussie mRNA facility